IP Library Patent Application 14739924
Patent Application
App. No. 14/739,924

Mesenchymal Stem Cells and Uses Therefor

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/739,924
Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Claims (8)

1 . A method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal comprising

administering genetically unmanipulated mesenchymal stem cells.

2 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 1 , wherein the genetically unmanipulated mesenchymal stem cells are administered in combination with an anti-inflammatory drug.

3 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 1 , wherein the animal is a mammal.

4 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 3 , wherein the mammal is a human.

5 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 1 , wherein the inflammatory bowel disease is Crohn's Disease.

6 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.

7 . The method of treating autoimmune encephalomyelitis, multiple sclerosis or inflammatory bowel diseases in an animal of claim 1 , wherein the inflammatory bowel disease is Graft Versus Host Disease of the gut.

Assignments (5)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 10, 2018
From: MESOBLAST INTERNATIONAL SARL
To: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 046515/0222 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 041453/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 041453/0169 →